Receiver operating curve analysis reported that cyclin D1 was used to differentiate between NPC patients and non‐NPC patients (P < .001, sensitivity: 53.6%, specificity: 85.7%, AUC = 0.752). This evidence concerns the gene CCND1 and nasopharyngeal carcinoma.